| Title |
Atriplatrade mark - HIV therapy in one pill.
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, June 2008
|
| DOI | 10.2147/tcrm.s2205 |
| Pubmed ID | |
| Authors |
Boris Julg, Johannes R Bogner |
| Abstract |
In July 2006 Atriplatrade mark was approved by the US Food and Drug Administration (FDA), combining the active ingredients of one NNRTI and two NRTIs. Atriplatrade mark is the first "one-pill-daily" regimen licensed for the treatment of HIV-1 infection in patients older than 18 years. H was licensed in Europe in December 2007 Atriplatrade mark contains efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg. It therefore combines 3 compounds which have been widely used before and which were recommended for initial therapy due to their potency, tolerability, and safety profile. Efficacy and safety data of efavirenz, tenofovir DF, and emtricitabine are reviewed and compared with other antiretroviral drugs, which are used as initial therapy for treatment-naive patient. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 2 | 22% |
| Student > Bachelor | 2 | 22% |
| Student > Doctoral Student | 1 | 11% |
| Student > Master | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 2 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 33% |
| Agricultural and Biological Sciences | 2 | 22% |
| Chemistry | 1 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
| Unknown | 2 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 March 2014.
All research outputs
#8,537,346
of 25,377,790 outputs
Outputs from Therapeutics and Clinical Risk Management
#461
of 1,323 outputs
Outputs of similar age
#33,978
of 97,662 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 8 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,662 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.